康复新液联合雷贝拉唑三联疗法治疗消化性溃疡疗效及对炎性因子和血液流变学的影响
|
摘要
【目的】探讨康复新液联合雷贝拉唑三联疗法治疗消化性溃疡(peptic ulcer,PU)的疗效及对患者炎性因子和血液流变学的影响。【方法】符合入选标准的80例PU患者按治疗方案随机分为观察组(n=40)和对照组(n=40)。对照组给予口服雷贝拉唑+阿莫西林+左氧氟沙星片,观察组在对照组的基础上加用康复新液。观察比较两组患者治疗效果、幽门螺杆菌(helicobacter pylori,Hp)根除率、炎性因子、血液流变学指标变化,记录不良反应发生情况。并随访1年,观察比较PU复发率。【结果】观察组治疗总有效率、Hp根除率为:97.5%、92.5%,对照组为:80.0%、87.5%,观察组治疗总有效率高于对照组(P<0.05),而Hp根除率两组间比较无统计学差异(P>0.05)。疗程结束后1周及2周时复查,观察组的炎性因子水平和血液流变学指标较对照组下降,且有统计学差异(P<0.05)。治疗过程中,两组不良反应轻微,不影响治疗。随访1年,观察组的PU复发率为2.6%,明显低于对照组21.9%(P<0.05)。【结论】康复新液联合雷贝拉唑三联疗法是治疗PU的有效方案,具有较高的临床缓解率,并能有效减轻炎性反应,改善血液流变学指标,降低复发率,临床上值得进一步研究。
【Objective】To investigate the clinical effect of kangfuxin solution in combination with rabeprazole-based triple therapy in the treatment of peptic ulcer(PU) and its effects on inflammatory factors and hemorheology.【Methods】80 cases of PU matching the inclusion criteria were randomly divided into 2 groups according to the therapeutic scheme. The control group was treated with rabeprazole+amoxicillin+levofloxacin and the observation group was treated with kangfuxin solution and rabeprazole-based triple therapy. Then, the curative efficacy,eradicating rate of helicobacter pylori(Hp), inflammatory factors, hemorheological parameters were observed and compared., adverse reactions were recorded and the recurrence rate were observed and compared during the one-year follow-up【Results】The observation group had a therapeutic efficiency ratio of 97.5% and a Hp eradication rate of 92.5%, which was respectively statistically higher than that of 80.0%(P<0.05) and statistically same with that of 87.5%(P>0.05) in the control group. Compared with the control group one week and two weeks after the treatment, inflammatory factors of TNF- α, IL- 6, CRP and hemorheological parameters of hematocrit, plasma viscosity, erythrocyte aggregation index, erythrocyte sedimentation rate was significantly lower respectively in the observation group(P<0.05). During the treatment,mild adverse reactions and no influence on the treatment occurred in the two groups. In the one-year follow-up, the observation group had a recurrence rate of 2.6%, which was significantly lower than that of 21.9% in the control group(P<0.05).【Conclusion】Combined treatment of kangfuxin solution with rabeprazole-based triple therapy is an effective solution for treatment which has a high clinical remission rate, can effectively relieve the inflammatory reaction, improve hemorheology index, and reduce the recurrence rate. It is worth further study in clinic.
【Objective】To investigate the clinical effect of kangfuxin solution in combination with rabeprazole-based triple therapy in the treatment of peptic ulcer(PU) and its effects on inflammatory factors and hemorheology.【Methods】80 cases of PU matching the inclusion criteria were randomly divided into 2 groups according to the therapeutic scheme. The control group was treated with rabeprazole+amoxicillin+levofloxacin and the observation group was treated with kangfuxin solution and rabeprazole-based triple therapy. Then, the curative efficacy,eradicating rate of helicobacter pylori(Hp), inflammatory factors, hemorheological parameters were observed and compared., adverse reactions were recorded and the recurrence rate were observed and compared during the one-year follow-up【Results】The observation group had a therapeutic efficiency ratio of 97.5% and a Hp eradication rate of 92.5%, which was respectively statistically higher than that of 80.0%(P<0.05) and statistically same with that of 87.5%(P>0.05) in the control group. Compared with the control group one week and two weeks after the treatment, inflammatory factors of TNF- α, IL- 6, CRP and hemorheological parameters of hematocrit, plasma viscosity, erythrocyte aggregation index, erythrocyte sedimentation rate was significantly lower respectively in the observation group(P<0.05). During the treatment,mild adverse reactions and no influence on the treatment occurred in the two groups. In the one-year follow-up, the observation group had a recurrence rate of 2.6%, which was significantly lower than that of 21.9% in the control group(P<0.05).【Conclusion】Combined treatment of kangfuxin solution with rabeprazole-based triple therapy is an effective solution for treatment which has a high clinical remission rate, can effectively relieve the inflammatory reaction, improve hemorheology index, and reduce the recurrence rate. It is worth further study in clinic.
引文
[1]Prabhu V,Shivani A.An overview of history,pathogenesis and treatment of perforated peptic ulcer disease with evaluation of prognostic scoring in adults[J].Ann Med Health Sci Res,2014,4(1):22-29.
[2]张信,周和,孙宏慧,等.雷贝拉唑与奥美拉唑三联疗法治疗幽门螺杆菌阳性消化性溃疡疗效比较--附40例分析[J].新医学,2004,35(7):401-403.
[3]陶伟,张宁,杨力.慢性胃病及胃癌中幽门螺杆菌感染与血清胃蛋白酶原水平变化的关系[J].解放军医学杂志,2012,37(4):350-353.
[4]刘代江,刘纯伦,张瑶,等.共转染沉默5-LOX/COX-2基因对胃癌细胞SGC-7901生长的影响[J].解放军医学杂志,2012,37(5):444-448.
[5]陈雅慧,兰忠平,惠起源,等.RASSF1A及p53蛋白在胃黏膜病变中的表达及意义[J].解放军医学杂志,2012,37(6):664-665.
[6]王利营,杨云生,张雷,等.农村地区功能性胃肠病及其相关因素的调查研究[J].解放军医学杂志,2012,37(9):876-878.
[7]Hongo M,Kimpara T,Moriyama S,et al.Effect of rabeprazole,a novel proton pump inhibitor on intragastric p H in healthy volunteers[J].Tohoku J Exp Med,1998,186(1):43-50.
[8]吴文海.雷贝拉唑四联疗法与枸橼酸铋雷尼替丁三联疗法治疗幽门螺杆菌相关性消化性溃疡效果对比研究[J].解放军医药杂志,2014,26(2):69-71,74.
[9]李勇,孔先一,周存金,等.康复新液对胃溃疡愈合质量的影响[J].山东医药,2011,51(33):77-78.
[10]韩培显,路长安,胡守喜,等.康复新液联合三联疗法治疗胃溃疡疗效观察[J].临床军医杂志,2011,39(5):1005-1006.
[11]邓薇,张小田,高静,等.人再生基因蛋白Ⅳ和细胞角蛋白18在胃癌患者血清中的表达及临床意义[J].解放军医学杂志,2012,37(12):1142-1146.
[12]姚莉亚,徐立.消化性溃疡患者血清c反应蛋白和肿瘤坏死因子α水平测定的临床意义[J].现代消化及介入诊疗,2008,13(3):214-216.
[13]厉琴,刘畅,樊荣,等.消化性溃疡患者血清IL-2、IL-6和TGF-β1检测的临床意义[J].放射免疫学杂志,2013,26(2):143-144.
[14]黎莉,杨卫文,杨景林,等.康复新口服液联合三联疗法治疗消化性溃疡的疗效观察[J].华西药学杂志,2006,21(3):309-310.
[15]陆婉秋.康复新液联合三联疗法治疗儿童幽门螺杆菌阳性相关性慢性胃炎43例[J].中国中西医结合消化杂志,2010,18(2):115-116.
[16]丁佐龙.消化性溃疡复发危险因素及预防对策[J].临床和实验医学杂志,2012,11(17):1409-1410.
[17]谷慧敏.康复新液治疗消化性溃疡疗效分析[J].中国误诊学杂志,2011,11(24):5864-5864.
[18]杨竞,范楠楠,杨云生.共聚焦激光显微内镜在消化道肿瘤及癌前病变中的应用[J].解放军医学杂志,2012,37(11):1091-1098.
[2]张信,周和,孙宏慧,等.雷贝拉唑与奥美拉唑三联疗法治疗幽门螺杆菌阳性消化性溃疡疗效比较--附40例分析[J].新医学,2004,35(7):401-403.
[3]陶伟,张宁,杨力.慢性胃病及胃癌中幽门螺杆菌感染与血清胃蛋白酶原水平变化的关系[J].解放军医学杂志,2012,37(4):350-353.
[4]刘代江,刘纯伦,张瑶,等.共转染沉默5-LOX/COX-2基因对胃癌细胞SGC-7901生长的影响[J].解放军医学杂志,2012,37(5):444-448.
[5]陈雅慧,兰忠平,惠起源,等.RASSF1A及p53蛋白在胃黏膜病变中的表达及意义[J].解放军医学杂志,2012,37(6):664-665.
[6]王利营,杨云生,张雷,等.农村地区功能性胃肠病及其相关因素的调查研究[J].解放军医学杂志,2012,37(9):876-878.
[7]Hongo M,Kimpara T,Moriyama S,et al.Effect of rabeprazole,a novel proton pump inhibitor on intragastric p H in healthy volunteers[J].Tohoku J Exp Med,1998,186(1):43-50.
[8]吴文海.雷贝拉唑四联疗法与枸橼酸铋雷尼替丁三联疗法治疗幽门螺杆菌相关性消化性溃疡效果对比研究[J].解放军医药杂志,2014,26(2):69-71,74.
[9]李勇,孔先一,周存金,等.康复新液对胃溃疡愈合质量的影响[J].山东医药,2011,51(33):77-78.
[10]韩培显,路长安,胡守喜,等.康复新液联合三联疗法治疗胃溃疡疗效观察[J].临床军医杂志,2011,39(5):1005-1006.
[11]邓薇,张小田,高静,等.人再生基因蛋白Ⅳ和细胞角蛋白18在胃癌患者血清中的表达及临床意义[J].解放军医学杂志,2012,37(12):1142-1146.
[12]姚莉亚,徐立.消化性溃疡患者血清c反应蛋白和肿瘤坏死因子α水平测定的临床意义[J].现代消化及介入诊疗,2008,13(3):214-216.
[13]厉琴,刘畅,樊荣,等.消化性溃疡患者血清IL-2、IL-6和TGF-β1检测的临床意义[J].放射免疫学杂志,2013,26(2):143-144.
[14]黎莉,杨卫文,杨景林,等.康复新口服液联合三联疗法治疗消化性溃疡的疗效观察[J].华西药学杂志,2006,21(3):309-310.
[15]陆婉秋.康复新液联合三联疗法治疗儿童幽门螺杆菌阳性相关性慢性胃炎43例[J].中国中西医结合消化杂志,2010,18(2):115-116.
[16]丁佐龙.消化性溃疡复发危险因素及预防对策[J].临床和实验医学杂志,2012,11(17):1409-1410.
[17]谷慧敏.康复新液治疗消化性溃疡疗效分析[J].中国误诊学杂志,2011,11(24):5864-5864.
[18]杨竞,范楠楠,杨云生.共聚焦激光显微内镜在消化道肿瘤及癌前病变中的应用[J].解放军医学杂志,2012,37(11):1091-1098.